Gritstone bio 관리

관리 기준 확인 2/4

Gritstone bio CEO는 Andrew Allen, Aug2015 에 임명되었습니다 의 임기는 9.17 년입니다. 총 연간 보상은 $ 3.44M, 18.8% 로 구성됩니다. 18.8% 급여 및 81.2% 보너스(회사 주식 및 옵션 포함). 는 $ 34.96K 가치에 해당하는 회사 주식의 1.53% 직접 소유합니다. 34.96K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 6.4 년입니다.

주요 정보

Andrew Allen

최고 경영자

US$3.4m

총 보상

CEO 급여 비율	18.8%
CEO 임기	9.2yrs
CEO 소유권	1.5%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11

Recent updates

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14

CEO 보상 분석

Andrew Allen 의 보수는 Gritstone bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$133m
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$3m	US$646k	-US$138m
Sep 30 2023	n/a	n/a	-US$139m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$620k	-US$120m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$116m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$589k	-US$75m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$2m	US$569k	-US$105m
Sep 30 2020	n/a	n/a	-US$106m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$2m	US$533k	-US$94m
Sep 30 2019	n/a	n/a	-US$84m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$475k	-US$65m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$56m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$592k	US$436k	-US$41m

보상 대 시장: Andrew 의 총 보상 ($USD 3.44M )은 US 시장( $USD 650.00K ).

보상과 수익: 회사가 수익성이 없는 동안 Andrew 의 보상이 증가했습니다.

CEO

Andrew Allen (58 yo)

9.2yrs

테뉴어

US$3,444,071

보상

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph D., serves as Independent Director at Verge Analytics, Inc. since September 2021. He has also held clinical development leadership positions at Chiron Corpo...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrew Allen	Co-Founder	9.2yrs	US$3.44m	1.53% $ 35.0k
Erin Jones	Executive VP & COO	3.6yrs	US$1.52m	0.063% $ 1.4k
Karin Jooss	Executive VP and Head of Research & Development	3.6yrs	US$1.58m	0.39% $ 8.9k
Vassiliki Economides	Executive VP & CFO	3.3yrs	데이터 없음	0.059% $ 1.3k
James Cho	Chief Accounting Officer	3.8yrs	데이터 없음	0.070% $ 1.6k
George MacDougall	Director of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Stacy Proctor	Executive VP & Chief People Officer	3.3yrs	데이터 없음	데이터 없음
Matthew Hawryluk	Executive VP & Chief Business Officer	8.9yrs	데이터 없음	0.034% $ 776.2

3.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: GRTS.Q 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andrew Allen	Co-Founder	9.2yrs	US$3.44m	1.53% $ 35.0k
Elaine Jones	Independent Chairman of the Board	5.1yrs	US$176.00k	0% $ 0
Stephen Webster	Independent Director	less than a year	데이터 없음	0.021% $ 482.6
Lawrence Corey	Independent Director	2.2yrs	US$132.50k	0% $ 0
Timothy Chan	Member of Scientific Advisory Board	7.3yrs	데이터 없음	데이터 없음
Eugene Zhukovsky	Member of Scientific Advisory Board	5.5yrs	데이터 없음	0% $ 0
Graham Lord	Member of Scientific Advisory Board	7.3yrs	데이터 없음	데이터 없음
Naiyer Rizvi	Independent Director & Member of Scientific Advisory Board	8.3yrs	US$140.00k	0% $ 0
James Gulley	Member of Scientific Advisory Board	7.3yrs	데이터 없음	데이터 없음
Alessandro Sette	Member of Scientific Advisory Board	7.3yrs	데이터 없음	데이터 없음
Shefali Agarwal	Independent Director	3.3yrs	US$138.50k	0% $ 0
Clare Fisher	Independent Director	2.8yrs	US$136.50k	데이터 없음

6.4yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: GRTS.Q 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Gritstone bio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

New major risk - Share price stability

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Consensus revenue estimates decrease by 60%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Price target decreased by 16% to US$4.33

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Consensus revenue estimates decrease by 17%, EPS upgraded

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Consensus revenue estimates decrease by 37%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 12% to US$8.80

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Consensus revenue estimates fall by 40%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Price target increased by 20% to US$10.34

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Price target increased by 20% to US$10.34

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Consensus revenue estimates fall by 53%

Price target decreased by 14% to US$8.60

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.75

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Price target decreased to US$10.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone reaches six-month high on publication of data for cancer vaccine

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Consensus revenue estimates increase by 14%

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Price target increased to US$16.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio announces $80M credit facility

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

Price target increased to US$16.00

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$14.67